Boston Scientific launches Victory guidewire for treatment of peripheral arterial disease


Boston Scientific has begun the United States and European launch of its Victory guidewire, designed to facilitate crossing of resistant lesions and the placement and exchange of balloon catheters or other interventional devices within the peripheral vasculature. 

The company expects to launch the product in other international markets later this year and in 2013, subject to regulatory approvals. 

The Victory guidewires feature a broad matrix of high gram-load tip options ranging from 12g to 30g, designed to cross resistant lesions. A unique stainless steel core technology enables this wire to have superior torque for optimal steering and control. Hydrophilic coating provides enhanced lubricity to facilitate crossing resistant lesions. The Victory guidewires come in both 0.014” and 0.018” diameters with four different gram-load options offering clinical versatility and a range of pushability.


“Resistant lesions can be a challenge and I often need various tools to access, cross and treat these types of lesions,” said Derek Mittleider, interventional radiologist, director, Vascular and Interventional Radiology, Spectrum Medical Group. “The Victory wire’s high gram-load options and excellent torque-ability give me the extra push and steer-ability I need to get through these resistant lesions more easily, making these cases less challenging.”

“Physicians treating critical limb ischaemia patients typically require a variety of treatment options. Boston Scientific is committed to offering a wide variety of crossing solutions,” said Jeff Mirviss, president of the Boston Scientific Peripheral Interventions Division. “Victory guidewires complement our already broad portfolio of crossing solutions, inclusive of our market-leading angioplasty balloons, Rubicon Support Catheter and the TruePath CTO device. The Victory guidewires offer another option to cross these highly resistant lesions and potentially avoid the need for amputation.”